ranking fourth among cancer-related deaths. Despite all the major molecular advances and treatment breakthroughs, mainly targeted therapies, the cornerstone treatment of metastatic pancreatic cancer (mPC) remains cytotoxic chemotherapy. In 2016, more than 40 years after the introduction of gemcitabine in the management of mPC, the best choice for first-line treatment has not yet been fully elucidated. Two main strategies have been adopted to enhance treatment efficacy. The first strategy is based on combining non-cross resistant drugs, while the second option includes the development of newer generations of chemotherapy. More recently, two new regimens, FOLFIRINOX and gemcitabine/nab-paclitaxel (GNP), have both been shown to improve overall survival in comparison with gemcitabine alone, at the cost of increased toxicity. Therefore, the best choice for first line therapy is a matter of debate. For some authors, FOLFIRINOX should be the first choice in patients with an Eastern Cooperative Oncology Group score (0-1) given its lower hazard ratio. However, others do not share this opinion. In this paper, we review the main comparison points between FOLFIRINOX and GNP. We analyze the two pivotal trials to determine the similarities and differences in study design. In addition, we compare the toxicity profile of the two regimens as well as the impact on quality of life. Finally, we present studies revealing real life experiences and review the advantages and disadvantages of possible second-line therapies including their cost effectiveness. Author contributions: Kattan J initiated the review; Ghosn M, Ibrahim T and Assi T performed the review, analyzed the data and wrote first draft; Ghosn M, El Rassy E, Kourie HR and Kattan J, reviewed and commented on the paper; all authors provided final approval for the content.
INTRODUCTION
Adenocarcinoma of the pancreas is one of the most aggressive human cancers, ranking fourth among cancer related deaths [1] . Recent biomolecular progress has led to a better comprehension of pancreatic car cinogenesis; however, the revolutionary targeted and immune therapies have not shown any significant results [2] . Subsequently, cytotoxic drugs remain the backbone of treatment for metastatic pancreatic cancer (mPC). Gemcitabine has been the standard of care in mPC since 1996, providing a limited survival of six months due to the intrinsic capacity of cancer cells and the surrounding microenvironment to resist cytotoxicity [35] . More aggressive regimens were de veloped to overcome these resistance mechanisms. The combination of noncross resistant agents, GTX (gemcitabine, docetaxel and capecitabine) and PEFG (cisplatin, epirubicin, fluorouracil and gemcitabine), enhanced tumor shrinkage by acting on different stages of cell cycle and bypassing mechanisms of drug resistance [68] . In 2011, French investigators from the Groupe Tumeurs Digestives of Unicancer and the PRODIGE Intergroup published the results of a phase Ⅱ/Ⅲ trial that revealed a clinically significant survival benefit and better quality of life for a regimen combining 5FU/ leucovorin, oxaliplatin and irinotecan (FOLFIRINOX) at the expense of increased toxicity [9] . Another option is nabpaclitaxel, which is a second generation chemo therapy agent that exploits the ability of albumin to deliver the hydrophobic molecule, paclitaxel, to targeted tissues. Nabpaclitaxel was combined with gemcitabine in the multinational MPACT phase Ⅲ trial and added an OS benefit of 2.6 mo compared to single agent Gemcitabine [10, 11] . Table 1 summarizes the efficacy of the FOLFIRINOX and gemcitabine/nabpaclitaxel (GNP) as published in the pivotal studies of ACCORD/PRODIGE and MPACT trials, respectively.
The best choice for first-line therapy is a matter of debate. The National Comprehensive Cancer Network (NCCN) panel considers FOLFIRINOX as the first choice for Eastern Cooperative Oncology Group (ECOG) 01 patients given its lower HR for death, whereas nabpaclitaxel should be reserved for ECOG 2 patients (NCCN 2016). Conversely, ASCO and ESMO consider both regimens as acceptable treatment options for ECOG 01 patients [12, 13] . Indirect comparisons using the ESMO magnitude of clinical benefit scale show a higher score for the FOLFIRINOX regimen when compared to GNP (5/5 vs 2/5, with a higher score indicating a better regimen in terms of survival benefit and qua lity of life) [14] . In addition, a Bayesian metaanalysis comparing multiple systemic protocols in advanced pancreatic cancer showed a trend toward better survival with FOLFIRINOX compared to GNP [15] . In view of this debate, we conducted this review to discuss the main comparison points between FOLFIRINOX and GNP, including the design of the two pivotal trials, toxicity profiles, quality of life, real life experiences, choice of secondline therapy and cost effectiveness.
TRIAL DESIGN: PRODIGE VS MPACT
The PRODIGE and MPACT trials were both randomized controlled trials (RCTs) based on an intent to treat principle and included 342 and 861 patients with mPC, respectively. Both trials had nearly the same tumor characteristics [9, 16] . Additionally, the median age (61 years for both trials) and sex ratio (1.6 for PRODIGE and 1.3 for MPACT) were nearly identical. However, the French trial included only patients less than 76 years old with good performance status based on the ECOG evaluation system (ECOG 01). In contrast, the MPACT trial did not specify an age limit (age ranged from 27 to 86 years) and included patients with intermediate performance status based on the KPS system (KPS < 90 in nearly 42% of patients). In addition, the PRODIGE trial only included patients from French centers while the MPACT trial was a multinational study including patients from North America (63%), Australia (14%), and Eastern (15%) and Western Europe (9%). In addition, patients in the Gemcitabine arm of the PRODIGE trial received only 6 mo of therapy even if they were not progressing (17%), nearly half of whom did not continue. While some authors do not consider these differences important given that the survival curves of the gemcitabine arm in the two trials are "superimposable", others do not share this opinion. In fact, Gemcitabine is a wellknown drug that is tolerated in the elderly population, even in intermediate health systems such as that of Eastern Europe. The same is not true when a new drug such as nabpaclitaxel is added to gemcitabine. In fact, the forest plot in the MPACT study clearly shows an effect of age and country on hazard ratio. In the same sense, Tehfe et al [17] published an analysis of patients from Canada (a sub group of the MPACT trial) and showed an OS equal to 11.9 mo in the GNP arm compared to 7.1 mo in the gemcitabine arm with a hazard ratio of 0.76. However, this subgroup analysis included only 63 patients and was underpowered to detect a statistically significant result.
TOXICITY AND QUALITY OF LIFE
The toxicity profile of a chemotherapy regimen is a major contributor in its adoption. Based on the two trials, hematologic toxicity is in favor of the FOLFIRINOX regimen and includes a lower incidence of neutropenia (45% vs 38%) (although the use of GCSF was more common), anemia (7.8% vs 13%), and thrombocytopenia (9.1% vs 13%). The remain ing toxicities are listed in Table 1 [9, 16] . Peripheral neu ropathy attributed to Nabpaclitaxel is a particular debilitating toxicity; grade 3 peripheral neuropathy was encountered in 17% of the patients but improved to grade 1 toxicity or less in a median of 29 d [10] . Real life studies with a closer followup of patients showed fewer side effects compared to those reported in the clinical trials [18] . Chemotherapyinduced hair loss is often a major determinant of the treatment regimen selected and was more commonly encountered in the GNP regimen (50% vs 11.2%) [9, 16] . Overall, FOLFIRINOX remarkably improved global health status, emotional functioning and many of the symptoms of mPC, such as pain and anorexia (although FOLFIRINOX did not relieve diarrhea), in the first two months of treatment. It also showed significantly increased time to physical or cognitive deterioration [19] .
On the other hand, quality of life was not assessed in the MPACT trial. In contrast, GNP showed significant improvement in qualityadjusted survival in comparison to gemcitabine alone using the QualityAdjusted Time Without Symptoms or Toxicities (QTWiST) me thodology, despite the limitations of the QTWiST analysis and the lack of prospective quality of life data from the MPACT trial [8] . Because significant toxicity was not uncommon, more tolerable treatment regimens were created by modifying the administration or drug dosing sche dule. In the modified FOLFIRINOX regimens, either the 5fluorouracil bolus was omitted or the dose of irinotecan was reduced. Stein et al [20] published solid data in a prospective study, enrolling both locally advanced and mPC patients who received a modified FOLFIRINOX regimen including a 25% dose reduction in 5-FU or irinotecan. These modifications successfully maintained the efficacy of the drugs while significantly decreasing the toxicity profile (decreased neutropenia, vomiting and fatigue). Additional exploratory analyses of the MPACT trial showed that patients who had dose delays or reductions (71% and 41%, respectively) had better outcomes [8] . These practical changes are capable of modifying the tolerance profile of the drugs while preserving efficacy. Tables 2 and 3 compare the Table 1 Comparison of the pivotal studies approving FOLFIRINOX and gemcitabine/nab-paclitaxel in metastatic pancreatic cancer ACCORD/PRODIGE trial (FOLFIRINOX ) [9] MPACT trial (GNP) [10] failure. The disease control rate was 58% with a 17.5% overall response rate and OS of 8.8 mo. Twelve patients (21%) had an ECOG of 2, and 40% had grade 34 toxicities without any treatmentrelated deaths [25] . In another retrospective study by Zhang et al [26] , 28 patients treated with the same regimen showed less satisfactory results, with an OS of 23 wk.
Small retrospective studies assessed the efficacy of FOLFIRINOX in the second line setting with a modest improvement in OS, but none evaluated its efficacy after GNP [27, 28] . In fact, the only data available is from the exploratory analyses of the second line treatment of the MPACT trial, where FOLFIRINOX (despite demonstrating interesting data) was only administered to 18 patients (10.5% of the whole population), calling the use of this treatment sequence into question [16] . Consequently, definitive recommendations con cerning the optimal sequence of therapy cannot be made. The prospective data from the AGEO trial makes GNP a better and more plausible option as a second line option after FOLFIRINOX administration. However, large RCTs are needed to create newer guidelines.
classical to the modified form of FOLFIRINOX and GNP respectively [2023] .
CHOICE OF SECOND-LINE
The optimal treatment sequence dictates the choice of first-line treatment for mPC. In fact, in the PRODIGE trial, only 47% of the patients were fit enough to receive secondline therapy while only 12.5% of patients received a secondline therapy after initially receiving a gemcitabinebased combination, yet the median OS was limited to 4.4 mo among those receiving second line treatments. On the other hand, in the MPACT trial, 40% of the patients received additional therapy after GNP [24] . According to these data, similar numbers of patients were able to receive secondline therapy after either FOLFIRINOX or GNP.
Data on the administration of GNP after FOLFIRINOX failure in the literature is limited to a few retrospec tive studies with conflicting data. The AGEO trial, a prospective multicenter study, evaluated the use of GNP in the secondline setting after FOLFIRINOX [9] Stein et al [20] Modified FOLFIRINOX Mahaseth et al [21] (Modified FOLFIRINOX) Ghorani et al [22] 
COST-EFFECTIVENESS
In addition to weighing efficacy and safety, oncologists must evaluate financial considerations to choose the optimal chemotherapy regimen. In fact, the NCCN shows a tendency toward incorporating the financial burden of cancer drugs into its decisionmaking strategy. Costeffectiveness of each regimen is largely dependent on the societal willingnesstopay (WTP) threshold set by each country. For instance, setting the WTP in Canada at $130000 makes the FOLFIRINOX regimen the optimal strategy in mPC. However, decreasing the limit to $80000 renders Gemcitabine monotherapy the only possible therapeutic choice [29] . Similarly, the increased WTP threshold in Greece rendered the GNP protocol a potential option in the treatment of patients with mPC [30] . Both FOLFIRINOX and GNP showed consistent costeffectiveness and costutility with superior survival efficacy in independent analytical studies [31, 32] . However, it is not until recently that the values of each regimen were compared. The value of the di fferent regimens in mPC was compared based on Medicare rates, which take into consideration the cost and administration of the drug, hospitalization and management of associated adverse events. The monthly costs of FOLFIRINOX and GNP were $7234 and $12221 respectively. However, the cost of the overall treatment based on progression free survi val in each protocol was estimated at $46289 and $67216. FOLFIRINOX seemingly exhibits higher cost effectiveness than GNP according to these results. However, it is worth mentioning that the cost of the FOLFIRINOX regimen is mainly due to its toxicity profile. Dosing modifications could limit the incidence of serious side effects and thus further increase the costeffectiveness of this protocol (Monthly cost of FOLFIRINOX is $763 versus $9008 for the GNP protocol). Consequently, in September 2015, the National Institute for Health and Care Excellence recommended against the use of GNP in patients with mPC due to the limited benefits in comparison to the cost of the drug. An alternative cheaper option that might be considered is modified GNP (which is yet to be validated), which has an overall treatment cost of $36226 [33] .
CONCLUSION
Overall, both FOLFIRINOX and GNP result in better overall survival and quality of life. In the absence of direct comparison, the treatment choice for patients with mPC is determined by physical toxicity and financial cost, both of which favor the FOLFIRINOX regimen. Further studies should aim to evaluate the modified schedules and dosing of both regimens in multinational RCTs and search for biomarkers that predict response to treatment [34] . In addition, the choice of firstline therapy in the future may not be limited to these two regimens, as newly developed drugs/therapeutic strategies should be tested in clinical trials to find more efficacious options for patients with good performance status. 
